Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 343,866 |
Reported balance
After 2026-10-06 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-10-06 · Grant · Acquired 45,838 · Balance 343,866 F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 384,058 |
Reported balance
After 2026-10-06 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-10-06 · Grant · Acquired 40,192 · Balance 384,058 F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 314,058 |
Reported balance
After 2026-10-06 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-10-06 · Tax withholding · Disposed 70,000 · Balance 314,058 F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-10-06 · Disposition to issuer · Disposed 404,608 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 24, 2023 Filed May 26, 2023 00:18 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-23-015899 · rdgdoc.xml · derivative · entry 5 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 10,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On May 4, 2015, the reporting person was granted an option to purchase 229,837 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| May 24, 2023 Filed May 26, 2023 00:18 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $22.14 | $221,400.00 |
DisclosureSEC source: 0001437749-23-015899 · rdgdoc.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 273,118 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 11-15-2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.72 to $22.34, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 24, 2023 Filed May 26, 2023 00:18 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $2.06 | $20,600.00 |
DisclosureSEC source: 0001437749-23-015899 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2023 Filed May 18, 2023 01:53 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 125 | $18.71 | $2,338.75 |
DisclosureSEC source: 0001437749-23-015007 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 273,118 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 20, 2023 Filed Apr 21, 2023 23:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-23-010843 · rdgdoc.xml · derivative · entry 6 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 10,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On May 4, 2015, the reporting person was granted an option to purchase 229,837 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| April 20, 2023 Filed Apr 21, 2023 23:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $19.25 | $192,500.00 |
DisclosureSEC source: 0001437749-23-010843 · rdgdoc.xml · nonDerivative · entry 4 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 268,352 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 11-15-2022 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.15 to $19.50, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 20, 2023 Filed Apr 21, 2023 23:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $2.06 | $20,600.00 |
DisclosureSEC source: 0001437749-23-010843 · rdgdoc.xml · nonDerivative · entry 3 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 278,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2023 Filed Apr 21, 2023 23:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-23-010843 · rdgdoc.xml · derivative · entry 5 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 10,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On May 4, 2015, the reporting person was granted an option to purchase 229,837 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| April 19, 2023 Filed Apr 21, 2023 23:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $19.47 | $194,700.00 |
DisclosureSEC source: 0001437749-23-010843 · rdgdoc.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 268,352 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 11-15-2022 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.31 to $19.57, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 19, 2023 Filed Apr 21, 2023 23:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $2.06 | $20,600.00 |
DisclosureSEC source: 0001437749-23-010843 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 278,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 06, 2023 Filed Apr 10, 2023 23:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 2,093 | $20.03 | $41,922.79 |
DisclosureSEC source: 0001437749-23-009873 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,352 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 06, 2023 Filed May 17, 2023 01:49 UTC Amendment | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 2,093 | $20.03 | $41,922.79 |
DisclosureSEC source: 0001437749-23-014864 · rdgdoc.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 273,243 F2 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. F3 · balance_after: This reflects the total amount beneficially owned by the reporting person as of April 10, 2023. Subsequent Form 4's filed by the reporting person after April 10, 2023 do not currently reflect the vesting of the 4,891 shares. Read SEC document |
| March 31, 2023 Filed May 17, 2023 01:49 UTC Amendment | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionRestricted Stock Award · Derivative | 4,891 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-014864 · rdgdoc.xml · derivative · entry 3 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,891 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F1 · derivative.expiration_date: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| March 31, 2023 Filed May 17, 2023 01:49 UTC Amendment | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 4,891 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-014864 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 275,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F1 · price: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 23:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 741 | $20.62 | $15,279.42 |
DisclosureSEC source: 0001437749-23-008896 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,445 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 23, 2023 Filed Mar 24, 2023 23:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-23-007915 · rdgdoc.xml · derivative · entry 6 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 10,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On May 4, 2015, the reporting person was granted an option to purchase 229,837 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| March 23, 2023 Filed Mar 24, 2023 23:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $21.79 | $217,900.00 |
DisclosureSEC source: 0001437749-23-007915 · rdgdoc.xml · nonDerivative · entry 4 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,186 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 15, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.32 to $22.24, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 23, 2023 Filed Mar 24, 2023 23:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $2.06 | $20,600.00 |
DisclosureSEC source: 0001437749-23-007915 · rdgdoc.xml · nonDerivative · entry 3 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 22, 2023 Filed Mar 24, 2023 23:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-23-007915 · rdgdoc.xml · derivative · entry 5 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 10,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On May 4, 2015, the reporting person was granted an option to purchase 229,837 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| March 22, 2023 Filed Mar 24, 2023 23:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $21.44 | $214,400.00 |
DisclosureSEC source: 0001437749-23-007915 · rdgdoc.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,186 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.03 to $21.92, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 22, 2023 Filed Mar 24, 2023 23:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $2.06 | $20,600.00 |
DisclosureSEC source: 0001437749-23-007915 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2023 Filed Mar 10, 2023 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 415 | $22.95 | $9,524.25 |
DisclosureSEC source: 0001437749-23-006043 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,186 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 2,086 | $22.75 | $47,456.50 |
DisclosureSEC source: 0001437749-23-005444 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,601 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 09, 2023 Filed Feb 14, 2023 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 78 | $24.60 | $1,918.80 |
DisclosureSEC source: 0001437749-23-003208 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,687 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 02, 2023 Filed Feb 4, 2023 00:15 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-23-002521 · rdgdoc.xml · derivative · entry 8 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 10,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On May 4, 2015, the reporting person was granted an option to purchase 229,837 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| February 02, 2023 Filed Feb 4, 2023 00:15 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 9,000 | $24.95 | $224,550.00 |
DisclosureSEC source: 0001437749-23-002521 · rdgdoc.xml · nonDerivative · entry 6 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,765 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 15, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.53 to $25.35, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 02, 2023 Filed Feb 4, 2023 00:15 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 9,000 | $2.06 | $18,540.00 |
DisclosureSEC source: 0001437749-23-002521 · rdgdoc.xml · nonDerivative · entry 5 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2023 Filed Feb 4, 2023 00:15 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,000 | $23.91 | $23,910.00 |
DisclosureSEC source: 0001437749-23-002521 · rdgdoc.xml · nonDerivative · entry 4 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,765 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 15, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.74 to $24.07, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 02, 2023 Filed Feb 4, 2023 00:15 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 1,000 | $2.06 | $2,060.00 |
DisclosureSEC source: 0001437749-23-002521 · rdgdoc.xml · nonDerivative · entry 3 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2023 Filed Feb 4, 2023 00:15 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-23-002521 · rdgdoc.xml · derivative · entry 7 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 10,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On May 4, 2015, the reporting person was granted an option to purchase 229,837 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| February 01, 2023 Filed Feb 4, 2023 00:15 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $22.87 | $228,700.00 |
DisclosureSEC source: 0001437749-23-002521 · rdgdoc.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,765 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.63 to $23.24, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 01, 2023 Filed Feb 4, 2023 00:15 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $2.06 | $20,600.00 |
DisclosureSEC source: 0001437749-23-002521 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 02:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-23-000587 · rdgdoc.xml · derivative · entry 10 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 10,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On May 4, 2015, the reporting person was granted an option to purchase 229,837 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 02:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 9,500 | $18.49 | $175,655.00 |
DisclosureSEC source: 0001437749-23-000587 · rdgdoc.xml · nonDerivative · entry 8 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,826 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 15, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.97 to $18.75, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 02:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 9,500 | $2.06 | $19,570.00 |
DisclosureSEC source: 0001437749-23-000587 · rdgdoc.xml · nonDerivative · entry 7 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 02:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 500 | $17.71 | $8,855.00 |
DisclosureSEC source: 0001437749-23-000587 · rdgdoc.xml · nonDerivative · entry 6 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,826 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 15, 2022. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 02:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 500 | $2.06 | $1,030.00 |
DisclosureSEC source: 0001437749-23-000587 · rdgdoc.xml · nonDerivative · entry 5 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001437749-23-000587 · rdgdoc.xml · derivative · entry 9 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 10,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On May 4, 2015, the reporting person was granted an option to purchase 229,837 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 500 | $18.81 | $9,405.00 |
DisclosureSEC source: 0001437749-23-000587 · rdgdoc.xml · nonDerivative · entry 4 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,826 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 15, 2022. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 500 | $2.06 | $1,030.00 |
DisclosureSEC source: 0001437749-23-000587 · rdgdoc.xml · nonDerivative · entry 3 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 9,500 | $17.72 | $168,340.00 |
DisclosureSEC source: 0001437749-23-000587 · rdgdoc.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,826 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.52 to $17.89, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 9,500 | $2.06 | $19,570.00 |
DisclosureSEC source: 0001437749-23-000587 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2023 Filed Jan 11, 2023 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 20,939 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-000817 · rdgdoc.xml · derivative · entry 2 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,939 Underlying: Common Stock · 20,939 shares Expires not disclosed F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. Read SEC document |
| January 03, 2023 Filed Jan 11, 2023 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 20,939 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-000817 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,765 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2023 compensation. Read SEC document |
| December 28, 2022 Filed Dec 31, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 712 | $16.90 | $12,032.80 |
DisclosureSEC source: 0001437749-22-029955 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,826 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 436 | $19.93 | $8,689.48 |
DisclosureSEC source: 0001437749-22-028236 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,538 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 01:07 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 107 | $23.16 | $2,478.12 |
DisclosureSEC source: 0001437749-22-027399 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,974 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| September 29, 2022 Filed Oct 1, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 657 | $23.02 | $15,124.14 |
DisclosureSEC source: 0001437749-22-023338 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,081 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 00:04 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 425 | $23.44 | $9,962.00 |
DisclosureSEC source: 0001437749-22-021731 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,738 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 14, 2022 Filed Aug 17, 2022 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 411 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-020753 · rdgdoc.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,163 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.